SynthesisDermatology and therapy2026
Clinical Severity and Outcome Measures in Seborrheic Dermatitis: A Systematic Review.
Synthesis in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeborrheic dermatitis (SD) is a common chronic inflammatory dermatosis associated with substantial symptom burden and impaired quality of life. Despite increasing interest in development of advanced therapies for SD, standardization of outcome measures appears limited. We sought to understand how disease severity, symptoms, and quality of life are measured in seborrheic dermatitis clinical studies.
methodsWe conducted a systematic review of clinical studies (both interventional and observational) assessing SD severity and treatment response. Eligible studies were identified through comprehensive database searches (Embase, PubMed, Scopus, Cochrane Database of Systematic Reviews, CINAHL Complete) and screened according to predefined inclusion criteria. Outcome measures were categorized by framework (clinician, patient, or combined), assessed domain(s), instrument type, and temporal, geographic, and study design characteristics.
resultsA total of 215 studies were included in the final analysis. Most studies relied primarily on clinician-reported outcomes (ClinROs), with fewer than half incorporating any patient-reported outcomes (PROs). Investigator-defined ClinROs predominated, while formally named, SD-specific indices, such as the Seborrheic Dermatitis Area and Severity Index, were infrequently used. Core clinical signs, including erythema and scaling, were consistently assessed across multiple study decades, whereas subjective symptoms and quality-of-life domains were measured less consistently. Although the use of combined ClinRO + PRO frameworks increased over time, clinician-centered assessments remained dominant across study designs and regions.
conclusionOutcome measurement in seborrheic dermatitis research is heterogeneous and remains predominantly clinician-centered, with limited validation and inconsistent use of validated ClinRO or PRO instruments. Greater standardization of outcome frameworks and broader integration of PROs may improve comparability and better capture patient-relevant disease burden in SD clinical research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.